BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 1457284)

  • 21. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J; Silver R
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract]   [Full Text] [Related]  

  • 22. Plasma adrenomedullin and endothelin-1 levels are reduced and Raynaud's phenomenon improved by daily tadalafil administration in male patients with systemic sclerosis.
    Rosato E; Letizia C; Proietti M; Aversa A; Menghi G; Rossi C; Torella E; Cotesta D; Petramala L; Bruzziches R; Spera G; Pisarri S; Salsano F
    J Biol Regul Homeost Agents; 2009; 23(1):23-9. PubMed ID: 19321043
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P; Buskila D; Lee P; Urowitz MB
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of Raynaud's phenomenon with captopril.
    Tosi S; Marchesoni A; Messina K; Bellintani C; Sironi G; Faravelli C
    Drugs Exp Clin Res; 1987; 13(1):37-42. PubMed ID: 3297593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G; Corrado E; Genova C; Amato C; Raimondi F; Almasio PL; Novo S
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P; Amico D; Giacomelli R; Matucci-Cerinic M; Salsano F; Valentini G; Gabrielli A
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Management of systemic sclerosis--a review.
    Ng SC; Clements PJ; Paulus HE
    Singapore Med J; 1990 Jun; 31(3):269-72. PubMed ID: 2203150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE; Shea B; Welch V; Fenlon D; Pope JE
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Diagnosis and management of scleroderma peripheral vascular disease.
    Herrick A
    Rheum Dis Clin North Am; 2008 Feb; 34(1):89-114; vii. PubMed ID: 18329535
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Systemic sclerosis in childhood].
    Falcini F; Trapani S; Taccetti G; Tafi L
    Pediatr Med Chir; 1990; 12(6):593-9. PubMed ID: 2093880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of Raynaud's phenomenon with intravenous prostaglandin E1alpha-cyclodextrin improves endothelial cell injury in systemic sclerosis.
    Gardinali M; Pozzi MR; Bernareggi M; Montani N; Allevi E; Catena L; Cugno M; Bottasso B; Stabilini R
    J Rheumatol; 2001 Apr; 28(4):786-94. PubMed ID: 11327251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Thermographic and symptomatic effect of a single dose of sildenafil citrate on Raynaud's phenomenon in patients with systemic sclerosis: a potential treatment.
    Kumar N; Griffiths B; Allen J
    J Rheumatol; 2006 Sep; 33(9):1918-9. PubMed ID: 16960964
    [No Abstract]   [Full Text] [Related]  

  • 33. Losartan therapy for Raynaud's phenomenon and scleroderma: clinical and biochemical findings in a fifteen-week, randomized, parallel-group, controlled trial.
    Dziadzio M; Denton CP; Smith R; Howell K; Blann A; Bowers E; Black CM
    Arthritis Rheum; 1999 Dec; 42(12):2646-55. PubMed ID: 10616013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Current treatment of systemic sclerosis. Part II. Vascular and antifibrotic treatment].
    SiciƄska J; Rudnicka L
    Pol Merkur Lekarski; 2008 Aug; 25(146):196-200. PubMed ID: 18942347
    [TBL] [Abstract][Full Text] [Related]  

  • 35. D-penicillamine treatment of progressive systemic sclerosis (scleroderma): a comparison of clinical and in vitro effects.
    Shapiro LS; Prince RK; Buckingham RB; Rodnan GP
    J Rheumatol; 1983 Apr; 10(2):316-8. PubMed ID: 6864687
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE; Hodes R; Sundstrom WR; Cleeland CS
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progressive systemic sclerosis and penicillamine.
    Rodnan GP
    J Rheumatol Suppl; 1981; 7():116-20. PubMed ID: 6939873
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Progressive systemic sclerosis.
    Medsger TA
    Clin Rheum Dis; 1983 Dec; 9(3):655-70. PubMed ID: 6360519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Penicillamine therapy in systemic sclerosis.
    Jayson MI; Lovell C; Black CM; Wilson RS
    Proc R Soc Med; 1977; 70 Suppl 3(Suppl 3):82-8. PubMed ID: 122683
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Limited cutaneous systemic sclerosis: report of one case.
    Lin MC; Fu LS; Huang KY; Tsen CF; Liou JM; Chi CS
    Acta Paediatr Taiwan; 2001; 42(4):248-51. PubMed ID: 11550416
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.